Read more

May 14, 2021
1 min read
Save

Top in rheumatology: Mesenchymal stem cell injections, digital approaches in OA care

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A speaker at the 2021 OARSI World Congress said that synovial mesenchymal stem cell injections can suppress cartilage loss in patients with progressive osteoarthritis. It was the top story in rheumatology last week.

Another top story was about how the COVID-19 pandemic has transformed rheumatology care. Kim Bennell, PhD, chair of physiotherapy at the University of Melbourne, said the success of real-time or asynchronous interventions have led to the adoption of a range of digital methods that may continue to be used after the pandemic.

TelehealthPatient1_355945742
Source: Adobe Stock

Read these and more top stories in rheumatology below:

Mesenchymal stem cell injections represent cutting edge of OA intervention

Intra-articular injections of mesenchymal stem cells into the synovium may yield expression of a number of genes that inhibit progression of osteoarthritis, according to a speaker. Read more.

COVID-19 raises profile, utility of digital therapeutic approaches in OA

The COVID-19 pandemic forced the rheumatology community to adopt a number of telehealth and digital approaches in patient care, according to a speaker at the 2021 OARSI World Congress virtual meeting. Read more.

Tanezumab comparable to NSAIDs in WOMAC pain, function across OA patient subgroups

Data showed that two dosing regimens of tanezumab yielded comparable outcomes in pain and function as NSAIDs across a number of osteoarthritis patient subgroups. Read more.

Study offers alternative explanation to placebo effect in assessing pain in OA

The placebo effect on pain scores in osteoarthritis may be attributed to a phenomenon called “regression to the mean,” according to a presentation at the 2021 OARSI World Congress. Read more.

Guselkumab increases enthesitis resolution rates in psoriatic arthritis

Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those higher rates through 1 year, in patients with psoriatic arthritis, according to data published in Rheumatology. Read more.